NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
ID: 348406Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348406

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-204.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the NEI Collaborative Clinical Vision Research Project through a Coordinating Center grant (UG1 Clinical Trial Required). This grant aims to support large-scale clinical trials focused on evaluating interventions for vision disorders, requiring applicants to demonstrate the project's significance, innovation, and the capabilities of the Principal Investigators. The Coordinating Center will be responsible for providing scientific and technical leadership, managing trial data and safety oversight, and collaborating with various research centers. There is no explicit budget cap, and the optimal project duration is up to five years. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 25, 2026.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-204-Full-Announcement.html
    PAR-23-204.html
    The National Eye Institute (NEI) is offering funding opportunities for Collaborative Clinical Vision Research Projects through a Coordinating Center grant (UG1 Clinical Trial Required). The grant aims to support large-scale clinical trials focused on evaluating interventions for vision disorders. Key responsibilities of the Coordinating Center include providing scientific and technical leadership, managing trial data and safety oversight, and collaborating with various research centers. Applications for this competitive grant must adhere to strict guidelines and demonstrate the project's significance, innovation, and the capabilities of the Principal Investigators. Various types of institutions, including higher education and nonprofit organizations, are encouraged to apply. The optimal project duration is up to five years, and while there is no explicit budget cap, applications must accurately reflect project needs. This funding initiative emphasizes the NEI's commitment to advancing vision research and improving public health outcomes related to vision disorders.
    Similar Opportunities
    NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Collaborative Clinical Vision Research Project, specifically for Resource Center Grants (UG1 Clinical Trial Required). This initiative aims to support large-scale clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with a particular emphasis on evaluating complex interventions and providing essential services for multi-center trials. The NEI seeks to advance vision health through rigorous research, and applications are encouraged from a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties must submit their applications by May 25, 2026, and can find additional information and guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Eye Institute (NEI), has announced a Notice of Funding Opportunity (NOFO) for the NEI Collaborative Clinical Vision Research: Chair's Grant (UG1), aimed at supporting large-scale clinical trials focused on vision disorders. This funding opportunity is intended for projects that evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, specifically requiring a clinical trial with a clear scientific rationale and detailed study design. The NEI emphasizes the importance of these trials in advancing vision science and public health, with awards structured as cooperative agreements to ensure substantial NIH involvement in the research process. Interested applicants must submit their proposals by May 25, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Center Core Grant for Vision Research, aimed at enhancing collaborative vision research through shared resource and service cores for funded investigators. This grant supports institutions with eight or more active NEI-supported R01 grants, providing direct costs of up to $2 million or $2.5 million over five years, depending on the number of eligible grants at the institution. The program is designed to increase productivity and collaboration among researchers while offering high-quality services that would be too costly for individual projects, ultimately supporting the NEI's mission to advance understanding of vision disorders. Applications are due by September 30, 2023, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Eye Institute (NEI) for cooperative agreements (U01) aimed at supporting early-stage clinical trials that involve greater than minimal risk, specifically targeting interventions for vision disorders. This initiative encourages applications for Phase I or II trials that are backed by strong preliminary data and require compliance with NIH guidelines, including the establishment of a Data Monitoring and Safety Committee (DSMC) for safety oversight. The funding is crucial for advancing research in the screening, diagnosis, prevention, and treatment of vision disorders, with project budgets reflecting actual needs and a maximum project period of five years. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with the application deadline set for May 7, 2025.
    NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Clinical Research Study Planning Grant Program (R34), aimed at supporting the development of clinical trial protocols and procedures specifically for eye and vision-related studies. This grant facilitates the preparation of a comprehensive Manual of Procedures (MOP) and allows for preliminary studies to assess recruitment potential, without generating data on intervention effects. Grants may provide up to $150,000 per year for a maximum of two years, with applications due by May 7, 2025. Eligible applicants include a wide range of institutions, including educational, nonprofit, and government entities, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) to support the planning and development of clinical vision research studies. This grant program aims to advance knowledge in eye and vision conditions by funding the development of study protocols and manuals, as well as fostering collaborative research efforts, while explicitly prohibiting the generation of data from clinical trials or preclinical studies. Eligible organizations, including educational institutions and nonprofits, can apply for grants of up to $150,000 per year for a maximum of two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-358.html.
    NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Translational Research Program for Therapeutics (Funding Opportunity Number: PAR-25-363), aimed at advancing innovative therapeutic solutions for visual system diseases. This program seeks to support multidisciplinary teams in generating preclinical data that will facilitate the development of treatments leading to FDA Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications, particularly targeting significant ocular disorders such as retinal diseases and glaucoma. With a funding cap of $1 million annually for a maximum of three years, applicants must demonstrate milestone-driven progress in IND/IDE-enabling studies, with applications due by February 16, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) aimed at accelerating the translation of innovative laboratory research into therapeutic interventions for visual system diseases. This program employs a bi-phasic, milestone-driven mechanism consisting of an Exploratory (R61) phase lasting up to two years and a Developmental (R33) phase lasting up to three years, focusing on generating preclinical data that supports applications for Investigational New Drug (IND) or Investigational Device Exemption (IDE) submissions to the FDA. The initiative is designed to engage diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to foster collaborative efforts in ocular research, ultimately improving health outcomes through vision research. Interested applicants can find more information and guidelines at the provided link, with a funding ceiling of $500,000 and a submission deadline of March 16, 2025.
    NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI Regenerative Medicine Clinical Trial Planning Grant (R34) to support the development of clinical trial protocols aimed at restoring vision through cell regeneration. This grant is designed to fund essential activities such as creating a Manual of Procedures (MOP), obtaining regulatory approvals, and assessing the feasibility of clinical trials that involve regenerative strategies, particularly those utilizing stem cells. The initiative underscores the federal commitment to advancing vision restoration research, with a funding ceiling of $150,000 per year for projects lasting up to two years. Interested applicants, including various educational institutions and organizations, must adhere to strict submission guidelines via Grants.gov, with applications due by May 7, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Translational Research Program for Therapeutics, aimed at advancing innovative therapies for visual system diseases. This program utilizes a bi-phasic R61/R33 grant mechanism, where the R61 phase supports the refinement of preliminary data, and the R33 phase focuses on advancing promising candidates through FDA regulatory processes leading to Investigational New Drug (IND) applications. The initiative encourages multidisciplinary collaboration among scientists, clinicians, and regulatory experts, with a budget cap of $500,000 for R61 applications and $1,000,000 for R33 applications. Interested applicants must submit their proposals by March 17, 2025, with the program opening for applications on January 16, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.